Stephen R. Davis has been leading Acadia Pharmaceuticals Inc. as their President and CEO since September 2015, bringing over 20 years of experience in the pharmaceutical sector. Before taking the helm at Acadia, he was the Executive VP and COO...

Stephen R. Davis has been leading Acadia Pharmaceuticals Inc. as their President and CEO since September 2015, bringing over 20 years of experience in the pharmaceutical sector. Before taking the helm at Acadia, he was the Executive VP and COO at Heron Therapeutics, where he helped shape a new strategy for the company. His journey includes stints at Ardea Biosciences, where he played a key role in the company's growth and development. Aside from running Acadia, he's also been involved with various boards, showing his deep commitment to the biopharmaceutical field. Under his leadership, Acadia has focused on significant product launches and achieving clinical goals, notably with drugs like NUPLAZID and DAYBUE. In 2023, his total compensation was about $1.87 million, reflecting performance-driven bonuses, stock options, and a salary of around $862,120. He also previously served in multiple executive roles at Neurogen Corporation, which gives him a well-rounded view of the industry.